epirubicin has been researched along with Cardiac Diseases in 64 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (29.69) | 18.7374 |
| 1990's | 18 (28.13) | 18.2507 |
| 2000's | 17 (26.56) | 29.6817 |
| 2010's | 8 (12.50) | 24.3611 |
| 2020's | 2 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, G; Azar, M; Beitzen-Heineke, A; Goy, Y; Lund, GK; Molwitz, I; Muellerleile, K; Müller, V; Petersen, C; Schön, G; Seiffert, K; Shihada, S; Stehning, C; Tahir, E | 1 |
| Bi, L; Chen, W; Han, R; Zhang, H; Zhao, N | 1 |
| Jantunen, E; Kuittinen, O; Peroja, P; Prusila, REI; Turpeenniemi-Hujanen, T | 1 |
| Feola, M; Garrone, O; Lo Nigro, C; Merlano, M; Monteverde, M; Vivenza, D | 1 |
| Chen, H; Cheng, L; Kang, Y; Li, L; Pan, C; Shu, X; Sun, M; Wei, Z | 1 |
| Chen, H; Cheng, L; Kang, Y; Li, L; Pan, C; Shu, X; Sun, M; Xu, X | 1 |
| Aoi, S; Blum, RH; Fujii, T; Hortobagyi, GN; Kozuch, PS; Yamaguchi, N | 1 |
| Han, Q; Hu, R; Irwin, DM; Li, H; Man, Z; Mao, Y; Niu, G; Tan, H; Wang, X; Zhang, J; Zhang, Q; Zhang, X | 1 |
| Baubion, N; Buzyn, A; Decaudin, D; Delarue, R; Fourquet, A; Ghez, D; Hermine, O; Messas, E; Rubio, MT; Suarez, F; Varet, B; Willems, L | 1 |
| Catalani, O; Coumbos, A; du Bois, A; Harbeck, N; Jackisch, C; Jonat, W; Kreienberg, R; Lehle, M; Lichinitser, M; Lück, HJ; Manikhas, AG; Meerpohl, HG; Müller, V; Muscholl, M; Pauschinger, M; Thomssen, C; Tjulandin, S; Untch, M | 1 |
| Davidson, A; Dick, G; Pinkerton, R; Pritchard-Jones, K | 1 |
| Brémond, A; Clavère, P; Datchary, J; Facchini, T; Fargeot, P; Fumoleau, P; Goudier, MJ; Jacquin, JP; Kerbrat, P; Luporsi, E; Mihura, J; Monnier, A; Namer, M; Pourny, C; Ramos, R; Romestaing, P; Schraub, S; Seffert, P; Serin, D; Sztermer, JF | 1 |
| Aubourg, L; Bonnet, P; Bougnoux, P; Chajès, V; Germain, E; Grangeponte, MC | 1 |
| Blohmer, JU; du Bois, A; Ebert, A; Eidtmann, H; Emons, G; Harbeck, N; Heilman, V; Höffken, K; Jackisch, C; Kuhn, W; Langer, B; Lück, HJ; Meerpohl, HG; Muscholl, M; Pauschinger, M; Reichardt, P; Thomssen, Ch; Untch, M; Wallwiener, D; Wiese, W | 1 |
| Bonneterre, JM | 1 |
| Du Bois, A; Eidtmann, H; Emons, G; Harbeck, N; Himsl, I; Jackisch, C; Kahlert, S; Kreienberg, R; Kuhn, W; Langer, B; Lueck, HJ; Meerpohl, HG; Muscholl, M; Pauschinger, M; Schaller, G; Thomssen, C; Untch, M; Wallwiener, D; Wiese, W | 1 |
| Arsovski, O; Debourdeau, P; Gligorov, J; Lotz, JP | 1 |
| Avilés, A; Cleto, S; Huerta-Guzman, J; Nambo, JM; Neri, N; Talavera, A | 1 |
| Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D | 1 |
| Bukan, N; Cam, M; Comunoglu, C; Ercan, F; Guven, A; Yavuz, O | 1 |
| Angelucci, E; Baldini, L; Federico, M; Gavarotti, P; Gobbi, P; Iannitto, E; Levis, A; Liberati, M; Luminari, S; Marcheselli, L; Orsucci, L; Pavone, V; Ricardi, U; Ucci, G | 1 |
| Bramwell, V; Bruntsch, U; Cavalli, F; Decoster, G; Dombernowsky, P; Høst, H; Renard, G; Rozencweig, M; ten Bokkel Huinink, W; Van Glabbeke, M | 1 |
| Agata, N; Hirano, S; Iguchi, H; Tone, H; Wakazono, K | 1 |
| Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B | 1 |
| Arévila, N; Avilés, A; Díaz Maqueo, JC; García, R; Gómez, T; Nambo, MJ | 1 |
| Catimel, G; Chazard, M; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Soler-Michel, P; Spielmann, M | 1 |
| Berg, K; Jynge, P; Olsen, H; Schjøtt, J | 1 |
| Bellina, RC; Bruzzi, P; Carnino, F; Conte, PF; Cyrus, P; Del Mastro, L; Gallo, L; Garrone, O; Guelfi, M; Lionetto, R; Michelotti, A; Molea, N; Pronzato, P; Rosso, R; Testore, F; Tibaldi, C; Venturini, M; Vinke, J | 1 |
| Chambers, EJ; Cook, AM; Rees, GJ | 1 |
| Kastner, J; Kornek, G; Raderer, M; Weinländer, G | 1 |
| Karakiulakis, G; Paradelis, AG; Pispirigos, K | 1 |
| Baldini, E; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Dell'Anna, R; Gennari, A; Gentile, A; Innocenti, F; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Fosså, SD; Heilo, A; Hernes, EH; Ogreid, P; Paus, E; Vaage, S | 1 |
| Lopez, M; Vici, P | 1 |
| Avanzini, P; Baldini, L; Brugiatelli, M; Carotenuto, M; Clò, V; Di Renzo, N; Dini, D; Federico, M; Gobbi, PG; Lombardo, M; Silingardi, V; Vallisa, D | 1 |
| Bajamonde, A; Baselga, J; Eiermann, W; Fleming, T; Fuchs, H; Leyland-Jones, B; Norton, L; Paton, V; Pegram, M; Shak, S; Slamon, DJ; Wolter, J | 1 |
| Pagani, O; Trudeau, M | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Boomsma, F; De Vries, EG; Gietema, JA; Haaksma, J; Meinardi, MT; Sleijfer, DT; Van Den Berg, MP; Van Der Graaf, WT; Van Veldhuisen, DJ | 1 |
| Evans, WK; Feld, R; Gupta, S; Lassus, M; Shannon, P; Shepherd, FA; Walde, PL; Wierzbicki, R | 1 |
| Anjo, A; Levi, F; Reynes, M | 1 |
| abdel Wareth, A; Dardir, MD; el Khodari, A; el Mawla, NG; el Zawahry, H; Gaafar, R; Habboubi, N; Hamza, MR; Khaled, H | 1 |
| Atkinson, CH; Chapman, PJ; Dady, PJ; Evans, BD; Harvey, VJ; Kirk, AR; Perez, DJ; Robinson, BA | 1 |
| Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F | 1 |
| Cardiff, RD; Gribble, M; Kohler, M; Medrano, V; Meyers, FJ; Mitchell, EP; Quadro, R; Shiffman, R; William, L | 1 |
| Beretta, G; Fraschini, P; Labianca, R; Locatelli, C; Luporini, G; Tabiadon, D | 1 |
| Favalli, L; Lanza, E; Monti, E; Poggi, P; Rozza, A; Villani, F | 1 |
| Bandinelli, M; Bartalucci, S; Ciapini, A; Cini-Neri, G; Neri, B; Pacini, P | 1 |
| Alling, DW; Banks, SM; Dardir, MD; el-Aasar, AB; el-Grindy, MS; el-Mawla, NG; el-Zawahry, HM; Ferrans, VJ; Mikhael, YS | 1 |
| Choy, DT; Ma, HK; Ngan, HY; Sham, JS; Wong, LC | 1 |
| Blum, R; Fazzini, E; Green, MD; Hochster, HS; Muggia, FM; Speyer, J | 1 |
| Bishop, J; Brodie, G; Burns, W; Coates, A; Levi, J; Raghavan, D; Schwarz, M; Snyder, R; Tattersall, M; Thomson, D | 1 |
| Elisson, O | 1 |
| Daxenbichler, G; Hetzel, H; Lechner, W; Marth, C; Reider, W | 1 |
| Bartalucci, S; Cinelli, P; De Leonardis, V; De Scalzi, M; Neri, B | 1 |
| Mordeglia, F; Rivero, O | 1 |
| Bezwoda, WR | 1 |
| Kolarić, K; Potrebica, V; Stanovnik, M | 1 |
| Casper, ES; Cassidy, C; Currie, V; Geller, NL; Hakes, TB; Jain, KK; Kaufman, RJ; Petroni, GR; Schwartz, W; Young, CW | 1 |
| Di Pietro, N; Ganzina, F; Magni, O | 1 |
| Boveris, A; Llesuy, SF; Milei, J; Milei, S; Molina, H | 1 |
| Korcok, M | 1 |
5 review(s) available for epirubicin and Cardiac Diseases
| Article | Year |
|---|---|
Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Topics: Antibiotics, Antineoplastic; Bayes Theorem; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Odds Ratio; Patient Selection; Polyethylene Glycols; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2015 |
[Cardiac prevention: the oncologic point of view].
Topics: Age Factors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Heart; Heart Diseases; Humans; Liposomes; Paclitaxel; Razoxane; Risk Factors; Trastuzumab | 2004 |
European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Epirubicin; Europe; Heart Diseases; Humans; Razoxane | 1998 |
Epirubicin in combination with the taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Epirubicin; Heart Diseases; Humans; Paclitaxel; Taxoids | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
27 trial(s) available for epirubicin and Cardiac Diseases
| Article | Year |
|---|---|
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULE
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Heart Diseases; Humans; Middle Aged; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Heart Diseases; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Premenopause; Risk Factors; Survival Rate | 2003 |
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Genes, erbB-2; Heart Diseases; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prospective Studies; Trastuzumab | 2004 |
Long-term efficacy and toxicity of the FEC100 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Epirubicin; Female; Fluorouracil; Heart Diseases; Humans; Leukemia, Myelomonocytic, Acute; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome | 2004 |
Anthracycline and trastuzumab in breast cancer treatment.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Germany; Heart Diseases; Humans; Middle Aged; Prospective Studies; Receptor, ErbB-2; Stroke Volume; Time Factors; Trastuzumab; Treatment Outcome | 2004 |
Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-Free Survival; Doxorubicin; Echocardiography; Epirubicin; Female; Gated Blood-Pool Imaging; Heart; Heart Diseases; Hodgkin Disease; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome; Vinblastine | 2005 |
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Estrogen Antagonists; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Heart Diseases; Humans; Lymph Node Excision; Middle Aged; Neoplasms; Premenopause; Receptors, Steroid; Tamoxifen; Triptorelin Pamoate | 2006 |
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Female; Heart Diseases; Hodgkin Disease; Humans; Infections; Italy; Leukopenia; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Severity of Illness Index; Treatment Outcome; Vinblastine | 2008 |
Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Breast Neoplasms; Carubicin; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Female; Follow-Up Studies; Heart Diseases; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Random Allocation; Vomiting | 1984 |
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fever; Heart Diseases; Humans; Middle Aged; Neutropenia; Paclitaxel | 1996 |
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Razoxane | 1996 |
Comparison of mitozantrone and epirubicin in advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Epirubicin; Heart Diseases; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 1996 |
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Heart Diseases; Humans; Least-Squares Analysis; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Stroke Volume; Survival Analysis; Treatment Outcome | 1997 |
Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Estramustine; Gastrointestinal Diseases; Gonadotropin-Releasing Hormone; Heart Diseases; Humans; Leukopenia; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Thrombocytopenia | 1997 |
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Heart Diseases; Hematologic Diseases; Humans; Idarubicin; Italy; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Heart Diseases; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasms, Second Primary; Survival Rate | 2001 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2001 |
Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Heart Diseases; Humans; Lung Neoplasms; Male; Middle Aged | 1992 |
A phase II study of epirubicin in breast cancer.
Topics: Adult; Breast Neoplasms; Drug Evaluation; Echocardiography; Electrocardiography; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Myocardium; Neoplasm Metastasis; Radiography | 1991 |
A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Survival Analysis | 1991 |
Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Liver Neoplasms; Middle Aged; Remission Induction; Survival Rate | 1991 |
Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.
Topics: Animals; Creatine Kinase; Doxorubicin; Echocardiography; Epirubicin; Female; Heart; Heart Diseases; Humans; Isoenzymes; Male; Middle Aged; Myocardium; Neoplasms; Oxygen Consumption; Rats; Rats, Inbred Strains | 1989 |
Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Heart Diseases; Hematologic Diseases; Humans; Nausea; Neoplasm Staging; Nervous System Diseases; Ovarian Neoplasms; Random Allocation; South Africa | 1986 |
Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Fluorouracil; Heart Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Rectal Neoplasms; Sigmoid Neoplasms; Stomach Neoplasms | 1986 |
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Topics: Actuarial Analysis; Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Erythrocytes; Female; Heart Diseases; Hematologic Diseases; Humans; Middle Aged; Nausea; Physical Examination; Prospective Studies; Radionuclide Imaging; Random Allocation; Stroke Volume; Technetium | 1985 |
American symposium looks at new antineoplastic drug.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Epirubicin; Heart Diseases; Humans; Stereoisomerism | 1985 |
32 other study(ies) available for epirubicin and Cardiac Diseases
| Article | Year |
|---|---|
Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
Topics: Breast Neoplasms; Cardiotoxicity; Epirubicin; Female; Heart Diseases; Humans; Magnetic Resonance Imaging; Magnetic Resonance Imaging, Cine; Predictive Value of Tests; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Application of a combination of echocardiographic techniques in an experimental model of epirubicin-induced cardiotoxicity.
Topics: Animals; Biomarkers; Cardiotoxicity; Disease Models, Animal; Early Diagnosis; Echocardiography, Doppler, Color; Echocardiography, Doppler, Pulsed; Epirubicin; Heart Diseases; Male; Mice, Inbred BALB C; Myocardial Contraction; Myocardium; Observer Variation; Predictive Value of Tests; Reproducibility of Results; Time Factors; Troponin I; Ventricular Function, Left | 2020 |
Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Substitution; Epirubicin; Etoposide; Female; Follow-Up Studies; Heart Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Matched-Pair Analysis; Prednisone; Progression-Free Survival; Retrospective Studies; Rituximab; Vincristine | 2019 |
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.
Topics: Adult; Aged; Angiotensinogen; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Glutathione Transferase; Heart Diseases; Humans; Isoenzymes; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Renin-Angiotensin System | 2013 |
Early detection of anthracycline-induced cardiotoxicity using two-dimensional speckle tracking echocardiography.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Asymptomatic Diseases; Early Diagnosis; Epirubicin; Female; Heart Diseases; Humans; Lymphoma, B-Cell; Male; Middle Aged; Myocardial Contraction; Observer Variation; Predictive Value of Tests; Reproducibility of Results; Stroke Volume; Time Factors; Ultrasonography; Ventricular Function, Left | 2013 |
Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cardiac Output; Cyclophosphamide; Doxorubicin; Echocardiography; Echocardiography, Three-Dimensional; Epirubicin; Female; Heart Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Predictive Value of Tests; Prednisone; Rituximab; Sensitivity and Specificity; Troponin T; Vincristine | 2014 |
Xinmailong mitigated epirubicin-induced cardiotoxicity via inhibiting autophagy.
Topics: Animals; Autophagy; Cardiotonic Agents; Cardiotoxicity; Collagen; Disease Models, Animal; Drugs, Chinese Herbal; Epirubicin; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Gene Expression Regulation; Heart Diseases; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinase 9; Myocardium; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Stroke Volume; Time Factors; Tissue Inhibitor of Metalloproteinase-4; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta1; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2016 |
[High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Daunorubicin; Epirubicin; Female; Fluorouracil; Heart Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Neoplasms, Second Primary; Remission Induction; Stroke Volume | 2010 |
EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Kidney Diseases; Male; Neoplasms; Vincristine | 2002 |
Anthracycline-induced cardiac toxicity is not increased by dietary omega-3 fatty acids.
Topics: Adipose Tissue; Animals; Antibiotics, Antineoplastic; Diet; Electrocardiography; Epirubicin; Fatty Acids; Fatty Acids, Omega-3; Heart Diseases; Heart Function Tests; Myocardium; Oxidation-Reduction; Rats | 2003 |
Melatonin protects against epirubicin-induced cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Drug Therapy, Combination; Epirubicin; Extracellular Matrix Proteins; Glutathione; Heart Diseases; Immunoenzyme Techniques; Injections, Intraperitoneal; Lipid Peroxidation; Male; Malondialdehyde; Melatonin; Myocytes, Cardiac; Nitrates; Nitric Oxide; Nitrites; Rats; Rats, Wistar | 2007 |
Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
Topics: Animals; Doxorubicin; Electrocardiography; Epirubicin; Female; Heart Diseases; Myocardium; Myofibrils; Rats; Rats, Sprague-Dawley | 1994 |
Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Heart Diseases; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Ventricular Function, Left; Vincristine | 1993 |
Pretreatment with ischaemia attenuates acute epirubicin-induced cardiotoxicity in isolated rat hearts.
Topics: Adenosine Triphosphate; Animals; Antibiotics, Antineoplastic; Blood Pressure; Epirubicin; Heart Diseases; Heart Rate; In Vitro Techniques; Ischemic Preconditioning; L-Lactate Dehydrogenase; Male; Myocardium; Phosphocreatine; Rats; Rats, Wistar; Ventricular Function, Left | 1996 |
Serum troponin T levels in adults undergoing anthracycline therapy.
Topics: Adult; Antibiotics, Antineoplastic; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Heart Diseases; Humans; Middle Aged; Neoplasms; Time Factors; Troponin | 1997 |
Evaluation of cardiac subacute toxicity of epirubicin, chlorambucil, cisplatin, methotrexate and a homo-aza-steroid ester with antitumor activity in rats using serum biochemical parameters.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Aspartate Aminotransferases; Body Weight; Chlorambucil; Cisplatin; Creatine Kinase; Epirubicin; Heart Diseases; Isoenzymes; L-Lactate Dehydrogenase; Methotrexate; Rats | 1997 |
Epirubicin for adjuvant therapy in node-positive breast cancer.
Topics: Adjuvants, Pharmaceutic; Antibiotics, Antineoplastic; Breast Neoplasms; Clinical Trials as Topic; Epirubicin; Fees, Pharmaceutical; Female; Heart Diseases; Humans; Lymph Nodes | 2000 |
Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chronic Disease; Cross-Sectional Studies; Cyclophosphamide; Dyspnea; Epirubicin; Female; Fluorouracil; Heart Diseases; Humans; Long-Term Care; Middle Aged | 2002 |
[Contribution of electron microscopy to the study of anthracycline cardiotoxicity].
Topics: Animals; Doxorubicin; Epirubicin; Heart; Heart Diseases; Male; Mice; Microscopy, Electron; Myocardium | 1991 |
Epirubicin in non-oat cell lung cancer--response rates and the importance of immunopathology: a Northern California Oncology Group Study.
Topics: Adult; Aged; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Staining and Labeling; Statistics as Topic; Stereoisomerism | 1986 |
Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care | 1987 |
The rat model in the comparative evaluation of anthracyclines cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Doxorubicin; Electrocardiography; Epirubicin; Female; Heart Diseases; Myocardium; Organ Size; Rats; Rats, Inbred Strains | 1989 |
Cardiac morphologic and functional changes induced by epirubicin chemotherapy.
Topics: Adult; Breast Neoplasms; Epirubicin; Female; Heart Diseases; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 1989 |
4-epidoxorubicin in recurrent cervical cancer.
Topics: Adult; Carcinoma, Squamous Cell; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 1989 |
4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation; Epirubicin; Female; Heart Diseases; Humans; Liver Neoplasms; Male; Middle Aged | 1985 |
Phase I study of epirubicin given on a weekly schedule.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Small Cell; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged | 1987 |
Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
Topics: Anthraquinones; Doxorubicin; Epirubicin; Heart Diseases; Humans; Mitoxantrone | 1986 |
Estimation of cardiotoxicity of epirubicin-cisplatin by determination of myoglobin.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Epirubicin; Female; Genital Neoplasms, Female; Heart Diseases; Humans; Middle Aged; Myoglobin | 1986 |
Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens.
Topics: Adult; Breast Neoplasms; Carnitine; Doxorubicin; Echocardiography; Epirubicin; Female; Heart Diseases; Humans; Lung Neoplasms; Male; Middle Aged | 1987 |
[Epirubicin: an anthracycline of minor cardiotoxicity].
Topics: Animals; Doxorubicin; Epirubicin; Heart; Heart Diseases; Humans | 1987 |
Clinical toxicity of 4'-epi-doxorubicin (epirubicin).
Topics: Alopecia; Bone Marrow; Breast Neoplasms; Doxorubicin; Epirubicin; Heart; Heart Diseases; Humans; Nausea; Vomiting | 1985 |
Comparison of lipid peroxidation and myocardial damage induced by adriamycin and 4'-epiadriamycin in mice.
Topics: Animals; Chemical Phenomena; Chemistry; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Lipid Peroxides; Malondialdehyde; Mice; Myocardium; Vitamin A; Vitamin E | 1985 |